Global Health Research and Technology (BIGHEART), NUS
Professor Luke P. Lee joined NUS in 2016 as Director of the Biomedical Institute for Global Health Research and Technology (BIGHEART) and appointed as Associate President (International Research and Innovation) in the Office of the Deputy President (Research and Technology). He is also appointed a Tan Chin Tuan Centennial Professor and holds joint appointments in the Departments of Medicine, Surgery, Biomedical Engineering, Chemistry, and Physics.
Professor Lee received both his BA and PhD from UC Berkeley. He joined the faculty at UC Berkeley in 1999 after more than a decade of industry experience. He became the Lester John and Lynne Dewar Lloyd Distinguished Professor of Bioengineering in 2005. He also served as the Chair Professor in Systems Nanobiology at the Swiss Federal Institute of Technology (ETH, Zürich) from 2006 to 2007. He became Arnold and Barbara Silverman Distinguished Professor in 2010 and was reappointed again in 2015. His work at the interface of biological, physical, and engineering sciences for medicine has been recognized by many honours that include the IEEE William J. Morlock Award, NSF Career Award, Fulbright Scholar Award, and the HoAm Prize. He is a Fellow of the Royal Society of Chemistry and the American Institute of Medical and Biological Engineering (AIMBE).
His current research interests include quantum electron transfers in living organisms, molecular diagnostics of infectious and neurodegenerative diseases, and in vitro neurogenesis, with a focus both on studying fundamental quantum nanobiology and on solving ill-defined problems of global healthcare.
Predictive Biomarkers and Point-of-Care Diagnostics for Personalized Medicine
Friday, 16 January 2015 at 16:30
Add to Calendar ▼2015-01-16 16:30:002015-01-16 17:30:00Europe/LondonPredictive Biomarkers and Point-of-Care Diagnostics for Personalized MedicinePrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
In this talk, I will present the development of predictive personalized medicine by bridging the gap between bench and bedside: integrated molecular diagnostic systems (iMDx) and integrative microphysiological analysis platforms (iMAPs), which are ideal for predictive and prognostic human biomarkers discovery. The iMDx is a mobile point-of-care biomarkers detection system: it comprises a self-contained sample preparation from whole blood, multiplexed protein and ultrafast nucleic acid amplification assays on chip with a sample-to-answer readout platform. The iMAPs is an advanced human organs on chip platform that recapitulates physiologically relevant microenvironments and patient’s clinical conditions for identifying human biomarkers, secretome proteomics, human disease modeling, experimental medicine, drug screening, and toxicology. Additionally, I will also discuss the progress on patient-specific iPSCs-based iMAPs for personalized medicine. This emerging iMAPs technology has the potential to become an alternative to 2D and 3D cell cultures and animal models. In summary, I will share my vision for predictive personalized medicine with low-cost precision monitoring and digital recording/analysis of health conditions.
Add to Calendar ▼2015-01-15 00:00:002015-01-16 00:00:00Europe/LondonPrognostic, Predictive, and POC: Biomarkers from Research to ClinicPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com